Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.60 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.57 |
| ▸ | ELANE | P08246 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | F2RL3 | Q96RI0 | 4/20 | 0.51 |
| ▸ | RAD52 | P43351 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | F2R | P25116 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4884093 | 0.96 | AR (0.58) | ARPLA2G2AELANEMAPTKMT2A | |
| SCHEMBL4891631 | 0.92 | AR (0.56) | ARPLA2G2AELANEMAPTKMT2A | |
| SCHEMBL5428229 | 0.89 | AR (0.61) | ARPLA2G2AMAPTKMT2AMEN1 | |
| SCHEMBL4887461 | 0.87 | AR (0.51) | ARPLA2G2AELANEMAPTKMT2A | |
| SCHEMBL4892207 | 0.87 | PLA2G2A (0.58) | ARPLA2G2AELANEMAPTKMT2A | |
| SCHEMBL4887465 | 0.86 | AR (0.50) | ARPLA2G2AELANEMAPTKMT2A | |
| SCHEMBL4893267 | 0.85 | MAPT (0.69) | ARELANEMAPTKMT2AMEN1 | |
| SCHEMBL4886339 | 0.83 | PLA2G2A (0.55) | PLA2G2AMAPTKMT2AMEN1LMNA | |
| SCHEMBL6858317 | 0.82 | ELANE (0.51) | ARPLA2G2AELANEMAPTKMT2A | |
| SCHEMBL4884198 | 0.81 | PLA2G4A (0.54) | ARELANEMAPTKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080319046-A1 | SUBSTITUTED SULFONAMIDE-INDOLES | WYETH (US) | 2008-12-25 | — | — | US | disclosed |
| US-7442805-B2 | Substituted sulfonamide-indoles | WYETH (US) | 2008-10-28 | — | — | US | disclosed |
| US-7332521-B2 | Substituted indoles | WYETH (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070299126-A1 | Substituted pyrrole-indoles | WYETH (US) | 2007-12-27 | — | — | US | disclosed |
| US-7265148-B2 | Substituted pyrrole-indoles | WYETH (US) | 2007-09-04 | — | — | US | disclosed |
| EP-1682530-B1 | PYRROLE SUBSTITUTED INDOLES AS INHIBITORS OF PAI-1 | WYETH CORP (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1682530-A1 | SUBSTITUTED PYRROLE-INDOLES AS INHIBITORS OF PAI-1 | Wyeth (US) | 2006-07-26 | — | — | EP | disclosed |
| EP-1667970-A1 | HETEROCYCLIC- OR ARYLOXY, -THIO 0R -AMINO SUBSTITUTED INDOLES-2-CARBOXYLIC ACIDS OR ESTERS AS PAI-1 INHIBITORS | Wyeth (US) | 2006-06-14 | — | — | EP | disclosed |
| EP-1667969-A1 | SUBSTITUTED SULFONAMIDE-INDOLE-2-CARBOXYLIC ACID DERIVATIVES AS PAI-1 INHIBITORS | Wyeth (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20050119327-A1 | Substituted indoles | WYETH (US) | 2005-06-02 | — | — | US | disclosed |
| US-20050113439-A1 | Substituted pyrrole-indoles | WYETH (US) | 2005-05-26 | — | — | US | disclosed |
| US-20050096377-A1 | Substituted sulfonamide-indoles | WYETH (US) | 2005-05-05 | — | — | US | disclosed |
| WO-2005030756-A1 | SUBSTITUTED PYRROLE-INDOLES AS INHIBITORS OF PAI-1 | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030716-A1 | HETEROCYCLIC- OR ARYLOXY, -THIO OR -AMINO SUBSTITUTED INDOLES-2-CARBOXYLIC ACIDS OR ESTERS AS PAI-1 | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030715-A1 | SUBSTITUTED SULFONAMIDE-INDOLE-2-CARBOXYLIC ACID DERIVATIVES AS PAI-1 INHIBITORS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319046-A1 | SUBSTITUTED SULFONAMIDE-INDOLES | STS, TPST2, IDO2 | AR 877/4885PLA2G2A 3606/4885ELANE 1593/4885 |
| US-20050096377-A1 | Substituted sulfonamide-indoles | STS, TPST2, IDO2 | AR 877/4885PLA2G2A 3606/4885ELANE 1593/4885 |
| US-20050113439-A1 | Substituted pyrrole-indoles | IDO2, IDO1, TPH2 | AR 1791/4885PLA2G2A 3107/4885ELANE 2667/4885 |
| US-20070299126-A1 | Substituted pyrrole-indoles | IDO2, IDO1, TPH2 | AR 1791/4885PLA2G2A 3107/4885ELANE 2667/4885 |
| US-20050119327-A1 | Substituted indoles | IDO2, IDO1, TPH2 | AR 605/4885PLA2G2A 3041/4885ELANE 3601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.